Key Insights

Highlights

Treatment Research

1 treatments under study, led by Aumolertinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05826483Phase 1UnknownPrimary

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Showing all 1 trials

Research Network

Common Treatments

  • Aumolertinib1

Active Sponsors

  • Guangzhou Institute of Respiratory Disease1

Top Investigators

Related Conditions

  • Poor Performance Status1

Activity Timeline